Literature DB >> 18005849

The type of ATG matters -- natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius.

Olaf Penack1, Lars Fischer, Chiara Gentilini, Axel Nogai, Arne Muessig, Kathrin Rieger, Susanne Ganepola, Eckhard Thiel, Lutz Uharek.   

Abstract

Although ATG is frequently used in hematopoietic stem cell transplantation and solid organ transplantation, little is known on its effects on NK cells, which mediate important functions in post-transplantation immunology. We incubated peripheral blood lymphocytes of healthy donors with Thymoglobulin, Lymphoglobulin or ATG-Fresenius. Cell death and apoptosis of NK cells and T cells were determined by flow cytometry using propidium iodide and Annexin V. As expected, there were no significant differences between the different ATGs regarding their T cell toxicity. Surprisingly, we found profound differences between the different ATGs regarding their impact on NK cells: In clinically relevant concentrations Lymphoglobulin had less toxic effects on NK cells as compared to Thymoglobulin or ATG-Fresenius: the median percentages of apoptotic or necrotic NK cells in response to 1 mug/ml Lymphoglobulin, ATG-Fresenius and Thymoglobulin were 2%, 35% and 38%, respectively (p<0.001). This is the first report of differential effects of different ATGs on NK cells. Lymphoglobulin appears to be superior to Thymoglobulin or ATG Fresenius regarding the preservation of NK cell mediated immunity. Randomized trials addressing the impact of different ATGs on lymphocyte subpopulations in the clinical setting are urgently warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18005849     DOI: 10.1016/j.trim.2007.05.001

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  14 in total

1.  Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice.

Authors:  T Ruutu; A Gratwohl; T de Witte; B Afanasyev; J Apperley; A Bacigalupo; F Dazzi; P Dreger; R Duarte; J Finke; L Garderet; H Greinix; E Holler; N Kröger; A Lawitschka; M Mohty; A Nagler; J Passweg; O Ringdén; G Socié; J Sierra; A Sureda; W Wiktor-Jedrzejczak; A Madrigal; D Niederwieser
Journal:  Bone Marrow Transplant       Date:  2013-07-29       Impact factor: 5.483

Review 2.  Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease.

Authors:  James O J Davies; Kate Stringaris; A John Barrett; Katayoun Rezvani
Journal:  Cytotherapy       Date:  2014-05-20       Impact factor: 5.414

3.  Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with thymoglobulin GVHD prophylaxis.

Authors:  A B M Lim; J Storek; A Beligaswatte; M Collins; M Tacey; T Williamson; K Mason; E Li; M A Chaudhry; J A Russell; A Daly; J Szer; I Lewis; D Ritchie
Journal:  Bone Marrow Transplant       Date:  2015-02-02       Impact factor: 5.483

4.  Outcomes of peripheral blood stem cell transplantation patients from HLA-mismatched unrelated donor with antithymocyte globulin (ATG)-Thymoglobulin versus ATG-Fresenius: a single-center study.

Authors:  Wenrong Huang; Xiaoli Zhao; Yamin Tian; Tingting Cao; Yanfen Li; Zhanxiang Liu; Yu Jing; Shuhong Wang; Chunji Gao; Li Yu
Journal:  Med Oncol       Date:  2015-01-15       Impact factor: 3.064

5.  Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity.

Authors:  Diana Stauch; Annelie Dernier; Elizabeth Sarmiento Marchese; Kristina Kunert; Hans-Dieter Volk; Johann Pratschke; Katja Kotsch
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

6.  Use of natural killer cells as immunotherapy for leukaemia.

Authors:  Bartosz Grzywacz; Jeffrey S Miller; Michael R Verneris
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

7.  Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures.

Authors:  Giuseppina Bonanno; Paola Iudicone; Andrea Mariotti; Annabella Procoli; Annino Pandolfi; Daniela Fioravanti; Maria Corallo; Alessandro Perillo; Giovanni Scambia; Luca Pierelli; Sergio Rutella
Journal:  J Transl Med       Date:  2010-12-07       Impact factor: 5.531

8.  Apoptotic effects of antilymphocyte globulins on human pro-inflammatory CD4+CD28- T-cells.

Authors:  Christina Duftner; Christian Dejaco; Paul Hengster; Klaudija Bijuklic; Michael Joannidis; Raimund Margreiter; Michael Schirmer
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

9.  Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies.

Authors:  Sandra Paiano; Eddy Roosnek; Yordanka Tirefort; Monika Nagy-Hulliger; Stavroula Masouridi; Emmanuel Levrat; Michael Bernimoulin; Saadia Huguet; Alessandro Casini; Thomas Matthes; Kaveh Samii; Jakob R Passweg; Yves Chalandon
Journal:  Bone Marrow Res       Date:  2015-03-22

10.  KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.

Authors:  Daniel Weisdorf; Sarah Cooley; Tao Wang; Elizabeth Trachtenberg; Cynthia Vierra-Green; Stephen Spellman; Jennifer A Sees; Ashley Spahn; Jenny Vogel; Todd A Fehniger; Ann E Woolfrey; Steven M Devine; Maureen Ross; Edmund K Waller; Ronald M Sobecks; Joseph McGuirk; Betul Oran; Sherif S Farag; Tsiporah Shore; Koen Van Besien; Steven G E Marsh; Lisbeth A Guethlein; Peter Parham; Jeffrey S Miller
Journal:  Blood Adv       Date:  2020-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.